Sedron (alendronate)

PreclinicalSmall molecule

Sedron (alendronate) is one of 11 small molecule programs targeting Primary Hyperparathyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary HyperparathyroidismActive, not recruiting

Primary HyperparathyroidismPreclinical

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Primary Hyperparathyroidism

#DrugCompanyPhaseTrials

Sensipar

Amgen

Approved

10 2

Zometa

Pfizer

Approved

2 3

Prolia

Amgen

Approved

1 4

Fosamax

OOrganon and Co

Approved

2 5

AMG 333

Amgen

Approved

1 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Midamor

PPadagis LLC

Phase 3

1 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 9

Cinacalcet Hcl

Amgen

Phase 3

1 10

KHK7580

Kyowa Kirin Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Hyperparathyroidism1 trial

OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism

Completed·WWroclaw Medical University·N/A·NCT01889134·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sedron (alendronate). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sedron (alendronate) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sedron (alendronate). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wroclaw Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWroclaw Medical University

Sedron (alendronate)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Hyperparathyroidism1 trial

References

Drug Info

Quick Facts

Related News